Page 71 - 南京医科大学自然版
P. 71

第44卷第12期 刘加宝,张艳娟,王连生,等. 维立西呱联合“新四联”药物对扩张型心肌病心衰患者的治疗效果分析[J].
                 2024年12月                    南京医科大学学报(自然科学版),2024,44(12):1682-1689                      ·1685 ·


                2.2  维立西呱联合“新四联”对DCM心衰患者的治                        95.56)m]均显著改善(P 均<0.01)。肝肾功能及电
                疗效果评估                                             解 质 差 异 无 统 计 学 意 义(P > 0.05,表 2)。
                    维立西呱联合“新四联”药物治疗DCM心衰患者                        2.3  维立西呱联合“ARNI、BB、SGLT2i”对 DCM
                3个月后,LAD[(41.37±6.97)mm vs.(39.30±5.19)mm],       HFpEF患者心功能的影响
                LVEF[(41.02 ± 10.33)% vs.(46.43 ± 10.74)% )],         进一步分析显示,维立西呱联合“ARNI、BB、
                LVEDD[(61.40±7.65)mm vs.(58.56±7.03)mm)],NT       SGLT2i”对 DCM HFpEF 患者心功能具有显著改善
                ⁃ proBNP[1 642.5(936.4,4 019.0)ng/L vs. 659.3     作用。治疗前后比较,患者的 LVEF[(53.2±2.3)%
               (213.2,1 297.0)ng/L),MLHFQ(47.79 ± 9.67 vs.        vs.(57.1±3.1)%,P < 0.01)],LVEDD[(58.0±4.2)mm
                34.86±8.94),6MWT[(348.85±82.43)m vs.(401.76±      vs.(55.3 ± 3.0)mm,P < 0.01)],NT ⁃ proBNP[961.0

                                                  表1 43例患者基本信息及用药情况
                                        Table 1 Baseline characteristics and medication of 43 patients
                        Characteristic           Data                     Characteristic                Data
                  Male[n(%)]                   33(76.74)      Classification of HF according to LVEF[n(%)]
                  Age(years,x ± s)            046.47 ± 12.67    HFpEF                                 10(23.26)
                  Height(cm,x ± s)            166.13 ± 6.680    HFmrEF                                11(25.58)
                  Weight(kg,x ± s)            071.12 ± 13.41    HFrEF                                 22(51.16)
                  SBP(mmHg,x ± s)             118.76 ± 13.67  Medication[n(%)]
                  DBP(mmHg,x ± s)              77.92 ± 8.78     ARNI                                  40(93.02)
                  Heart rate(beats/min,x ± s)  075.56 ± 15.31   BB                                    38(88.37)
                  Medical history[n(%)]                         Furosemide                            36(83.72)
                    Hypertension               12(27.91)        MRA                                   37(86.04)
                    Diabetes mellitus          06(13.95)        SGLT2i                                39(90.70)
                  NYHA functional class[n(%)]                   Vericiguat                            43(100.00)

                    Ⅰ                           0(0)0.0         Digoxin                               21(48.84)
                    Ⅱ                          18(41.86)
                    Ⅲ                          22(51.16)
                    Ⅳ                           3(6.98)


                                         表2 维立西呱联合“新四联”对DCM心衰患者的疗效评估
                      Table 2 Efficacy evaluation of vericiguat combined with“new quadruple”drugs in DCM patients with HF(n=43)
                        Characteristic           Prior to medication     After medication      t/Z         P
                  LAD(mm,x ± s)                    41.37 ± 6.970         39.30 ± 5.190 0      4.278      <0.01
                  LVESD(mm,x ± s)                  49.47 ± 9.160         45.58 ± 8.740 0      5.260      <0.01
                  LVEDD(mm,x ± s)                  61.40 ± 7.650         58.56 ± 7.030 0      4.789      <0.01
                  LVEF(%,x ± s)                    41.02 ± 10.33         46.43 ± 10.740      -5.953      <0.01
                  NT⁃proBNP[ng/L,M(P25,P75)]   1 642.5(936.4,4 019.0)  659.3(213.2,1 297.0)  -5.700      <0.01
                  MLHFQ(x ± s)                     47.79 ± 9.670         34.86 ± 8.940 0      14.270     <0.01
                  6MWT(m,x ± s)                   348.85 ± 82.430       401.76 ± 95.560 0     2.767      <0.01
                  ALT(U/L,x ± s)                   26.68 ± 16.73         29.87 ± 18.120      -1.112      <0.273
                  AST(U/L,x ± s)                   25.80 ± 11.71         28.17 ± 9.160 0     -1.206      <0.235
                  Creatinine(μmol/L,x ± s)         92.78 ± 37.34         97.24 ± 50.200      -1.221      <0.229
                  Urea nitrogen(mmol/L,x ± s)      7.80 ± 4.42            7.70 ± 3.470        0.228      <0.820
                  K(mmol/L,x ± s)                  3.96 ± 0.45            4.09 ± 0.380       -1.762      <0.086
                   +
                  Na(mmol/L,x ± s)                140.30 ± 3.010        139.25 ± 2.780 00     1.854      <0.071
                    +
                  Cl(mmol/L,x ± s)                104.10 ± 3.830        103.28 ± 3.250 00     1.074      <0.289
                   -
                  Ca(mmol/L,x ± s)                 2.28 ± 0.15            2.31 ± 0.160       -1.146      <0.259
                    2+
   66   67   68   69   70   71   72   73   74   75   76